Fig. 1

SHP-1 agonist suppresses tumor growth through SHP-1/Lyn pathway in vivo. A–E U2932 tumor-bearing mice (N = 4) were treated with vehicle, SC-43 (10 and 30 mg/kg) or ibrutinib (12.5 and 25 mg/kg) orally three times a week. Tumor growth (A), tumor weights (B), and body weights (C) of mice were measured. The SHP-1 activity and protein expression levels of tumors were analyzed by Tyrosine Phosphatase Assay (D) and Western blot analysis (E). Student’s t-test, *P < 0.05